Proopiomelanocortin (POMC) disregulation and response to opiate blockers

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 4, 1999, Pages 314-321

  Sandman, Curt A ^a,c   Spence, M Anne ^b   Smith, Moyra ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NONE   (United States)

Author keywords

Autism; Naltrexone; Opiate blockers; Proopiomelanocortin

Indexed keywords

BETA ENDORPHIN; CALCIUM ION; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYCLIC AMP; FURIN; NALOXONE; NALTREXONE; OPIATE ANTAGONIST; PROOPIOMELANOCORTIN; SEROTONIN;

AUTISM; AUTOMUTILATION; DRUG EFFICACY; GENOTYPE; HUMAN; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW;

EID: 0033373436     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:4<314::AID-MRDD9>3.0.CO;2-G     Document Type: Review

References (101)

1. Anderson GM, Hoshino Y. 1987. Neurochemical studies of autism. In: Cohen DJ, Donnellan A, editors. Handbook of autism and pervasive developmental disorders. New York: John Wiley & Sons. p 166-191.
2. Anderson GM, Freedman DX, Cohen DJ, et al. 1987. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 28:85-90.
3. Arnsten AFT, Segal DS, Nevill HB, et al. 1983. Naloxone augments electrophysiological signs of selective attention in man. Nature 304:725-727.
4. Bardo MT, Neisewandler JL. 1987. Chronic naltrexone supersensitizes the reinforcing and locomotor-activating effects of morphine. Pharmacology Biochemistry & Behavior 28: 267-273.
5. Barrett RP, Feinstien C, Hole WT. 1989. Effects of naloxone and naltrexone on self-injury: A double-blind, placebo-controlled analysis. American Journal on Mental Retardation 93:644-651.
6. Belluzzi JD, Stein L. 1977. Enkephaline may mediate euphoria and drive-reduction reward. Nature 26:556-558.
7. Bertagna X. 1994. Proopiomelanocortin-derived peptides. Endocrinol Metab Clin North Am 23:467-485.
8. Bicknell AB, Savva D, Lowry PJ. 1996. Proopiomelanocortin and adrenal function. Endocr Res 22:385-393.
9. Bodfish JW, Powell SB, Golden RN, et al. 1995. Blink rate as an index of dopamine function in adults with mental retardation and repetitive behavior disorders. Am J Ment Retard 99:335-344.
10. Boutillier AL, Monnier D, Lorang D, et al. 1995. Corticotrophin-releasing hormone stimulates proopiomelanocortin transcription by cFos-dependent and -independent pathways: characterization of an AP1 site in exon 1. Mol Endocrinol 9:745-755.
11. Bouvard MP, Leboyer M, Launay JM, et al. 1995. Low-dose naltrexone effects on plasma chemistries and clinical symptoms in autism: a double-blind, placebo-controlled study. Psychiatry Res 58:191-201.
12. Bristol MM, Cohen DJ, Costello EJ, et al. 1996. State of the science in autism: report to the National Institutes of Health. J Autism Dev Disord 26:121-154.
13. Brunello N, Volterra A, DiGiulio AM et al. 1984. Modulation of opioid system in C57 mice after repeated treatment with morphine and naloxone: Biochemical and behavioral correlates. Life Sciences 34:1669-1678.
14. Casner JA, Weinheimer B, Gualtiere CT. 1996. Naltrexone and self-injurious behavior: a retrospective population study. Journal of Clinical Psychopharmacology 16:389-394.
15. Casner JA, Weinheimer B, Gualtieri CT. 1996. Naltrexone and self-injurious behavior: a retrospective population study. J Clin Psychopharmacol 16:389-394.
16. Cataldo MF, Harris J. 1982. The biological basis for self-injury in the mentally retarded. Analysis Interven Dev Disabil 2:21-39.
17. Coid J, Allolio B, Rees LH. 1983. Raised plasma metenkephalin in patients who habitually mutilate themselves. Lancet 2:545-546.
18. Comuzzie AG, Hixon JE, Almasy L, et al. 1997. A major quanitative trait locus determining serum leptin levels and fat mass is located on human chromosome 2. Nature Genet 15:273-275.
19. Cook EH Jr, Courchesne R, Lord C, et al. 1997. Evidence of linkage between the serotonin transporter and autistic disorder. Mol Psychiatry 2:247-250.
20. Crain SM, Shen KF. 1995. Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment. Proceedings of the National Academy of Science of the United States of America 92:10540-10544.
21. Crews WD Jr., Bonaventrus S, Rowe FB et al. 1983. Cessation of long-term naltrexone therapy and self-injury: A case study. Research in Developmental Disabilities 14:331-340.
22. Davidson PW, Kleene BM, Caroll M, et al. 1983. Effects of naloxone on self-injurious behavior: a case study. Appl Res Ment Retard 4:1-4.
23. Dehen H, Willer JC, Boureau F, et al. 1977. Congenital insensitivity to pain, and endogenous morphine-like substances. Lancet 2:293-294.
24. Demet E, Sandman CA. 1991. Models of opiate system in self-injurious behavior: a reply. Am J Ment Retard 95:694-697.
25. Deutsch SI. 1986. Rationale for the administration of opiate antagonists in treating infantile autism. Am J Ment Retard 90:631-635.
26. Dunger DB, Leonard JV, Wolff OH, et al. 1980. Effect of naloxone in a previously undescribed hypothalamic syndrome. Lancet 1:1277-1281.
27. Ernst M, Devi L, Silva RR, et al. 1993. Plasma beta-endorphin levels, naltrexone, and haloperidol in autistic children 29:221-227.
28. Farber JM. 1987. Psychopharmacology of self-injurious behavior in the mentally retarded. J Am Acad Child Adolesc Psychiatry 26:296-302.
29. Flejter WL, Bennett-Baker P, Ghaziuddin M, et al. 1996. Cytogenetic and molecular analysis of inv dup (15) chromosomes observed in two patients with autistic disorder and mental retardation. Am J Med Genet 61:182-187.
30. Forman LJ, Cavalieri R, Estilow S, et al. 1990. The elevation of immunoreactive b-endorphin in old male rats is related to alterations in dopamine and serotonin. Neurobiol Aging 11:223-227.
31. Ganguly A, Prockop DJ. 1990. Detection of single-base mutations by reaction of DNA heteroduplexes with a water-soluble carbodiimide followed by primer extension: application to products from the polymerase chain reaction. Nucleic Acids Res 18:3933-3939.
32. Gen K, Toshiaki H, Kato T, et al. 1994. Presence of the same transcript of pro-opiomelanocortin (POMC) genes in the porcine anterior and intermediate pituitary lobes. Mol Cell Endocrinol 103:101-108.
33. Gillberg C. 1992. Autism and autistic-like conditions: subclasses among disorders of empathy. J Child Psychol Psychiatry 33:813-842.
34. Gillberg C. 1995. Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians. Dev Med Child Neurol 37:88-92.
35. Gillberg C, Terenius LG, Lonnerhom G. 1985. Endorphin activity in childhood psychosis. Arch Gen Psychiatry 42:780-783.
36. Gillberg C, Terenius LG, Hagberg B, et al. 1990. CSF beta-endorphins in childhood neuropsychiatric disorders. Brain Dev 12:88-92.
37. Giuffre KA, Udelsman R, Listwak S, et al. 1988. Effects of immune neutralization of corticotropin-releasing hormone, adrenocorticotropin, and b-endorphin in the surgically stressed rat. Endocrinology 122:306-310.
38. Gonzalez JP, Brogden RN. 1988. Naltrexone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence. Drugs 35:192-213.
39. Gordon CT, State RC, Nelson JE, et al. 1993. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447.
40. Green AH. 1967. Self-mutilation in schizophrenic children. Arch Gen Psychiatry 17:234-244.
41. Holson RR, Scallet AC, Ali SF, et al. 1988. Adrenocortical, b-endorphin and behavioral responses to graded stressors in differentially reared rats. Physiol Behav 42:125-130.
42. Hotopf M, Bolton P. 1995. A case of autism associated with partial tetrasomy 15. J Autism Dev Disord 25:41-49.
43. Insel TR. 1997. A neurobiological basis of social attachment. Am J Psychiatry 154:726-735.
44. Iwata BA, Dorsey MF, Slifer KJ, et al. 1982. Toward a functional analysis of self-injury. Am J Psychiatry 154:726-735.
45. Jackson RS, Creemers J, Ohagi S, et al. 1997. Obesity and impaired prohormone processing associated with mutations in the human prohormone convertase 1 gene. Nat Genet 16:303-306.
46. Japon MA, Rubinstein M, Low MJ. 1994. In situ hybridization analysis of anterior pituitary hormone gene expression during fetal mouse development. J Histochem Cytochem 42: 1117-1125.
47. Knigge U, Matzen S, Bach F, et al. 1989. Involvement of histaminergic neurons in the stress-induced release of pro-opiomelanocortin-derived peptides in rats. Acta Endocrinol (Copenh) 120:533-539.
48. Krude H, Biebermann H, Luck W, et al. 1998. Severe early-onset obesity, adrenal insufficiency and red hair pigmentation caused by POMC mutations in humans. Nat Genet 19:155-157.
49. Lal H. 1975. Narcotic dependence, narcotic action, and dopamine receptors. Life Sci 17:483-496.
50. LeBoyer M, Bouvard MP, Recasens C, et al. 1994. Difference between plasma N- and C-terminally directed beta-endorphin immunoreactivity in infantile autism. Am J Psychiatry 151:1797-1801.
51. Leboyer M, Philippe A, Bouvard M, et al. 1999. Whole blood serotonin and plasma beta-endorphin in autistic probands and their first-degree relatives. Soc Biol Psychiatry 45:158-163.
52. Lewis MH, Bodfish JW, Powell SB, et al. 1995. Clomipramine treatment for stereotypy and related repetitive movement disorders associated with mental retardation. Am J Ment Retard 100:299-312.
53. Lewis MH, Bodfish JW, Powell SB, et al. 1996a. Clomipramine treatment for self-injurious behavior of individuals with mental retardation: a double-blind comparison with placebo. Am J Ment Retard 100:654-665.
54. Lewis MH, Bodfish JW, Powell SB, et al. 1996b. Brief reports: plasma HVA in adults with mental retardation and stereotyped behavior: biochemical evidence for a dopamine deficiency model. Am J Ment Retard 100:413-427.
55. MacKay D, McDonald G, Morrissey M. 1974. Self-mutilation in the mentally subnormal. J Psychol Res Ment Subnorm 1:25-30.
56. Madden JI, Akil H, Patrick RL, et al. 1977. Stress-induced parallel changes in central opioid levels and pain responsiveness in the rat. Nature 265:358-360.
57. Marley RJ, Shimosato K, Gewiss M et al. 1995. Long-term sensitization to the behavioral effects of naltrexone is associated with regionally specific changes in the number of μ and δ opioid receptors in rat brain. Life Sciences 56:767-774.
58. Martinsson T, Johannesson T, Vujicic M, et al. 1996. Maternal origin of inv dup (15) chromosomes in infantile autism. J Eur Child Adolesc Psychiatry 5:185-192.
59. Matson JL, Keyes JB. 1990. A comparison of DRO to movement suppression time-out and DRO with two self-injurious and aggressive mentally retarded adults. Res Dev Disabil 11:111-120.
60. Matson JL, Taras ME. 1989. A 20 year review of punishment and alternative methods to treat problem behaviors in developmentally delayed persons. Res Dev Disabil 10:85-104.
61. McDougle CJ, Holmes JP, Bronson MR, et al. 1997. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective, open-label study. J Am Acad Child Adolesc Psychiatry 36:685-693.
62. Oltras CM, Mora F, Vives F. 1987. B-endorphin and ACTH in plasma: effects of physical and psychological stress. Life Sci 40:1683-1686.
63. Panksepp J, Lening P. 1991. Brief report: A synopsis of an open-trial of naltrexone treatment of autism with four children. Journal of Autism and Developmental Disorders 21:243-249.
64. Rapin I. 1997. Autism. N Engl J Med 337:97-104.
65. Recher H, Willis GL, Smit GC, et al. 1988. B-endorphin, corticosterone, cholesterol and triglyceride concentrations in rat plasma after stress, cingulotomy or both. Pharmacol Biochem Behav 31:75-79.
66. Reisine T, Pasternak G. 1996. Opioid analgesics and antagonists. In: Hardman JG, Limbird LE, Molinoff PB, et al., editors. The pharmacological basis of therapeutics. New York: McGraw-Hill. p 521-556.
67. Rincover A, Devany J. 1982. The application of sensory extinction procedures to self-injury. Anal Interv Dev Disabil 2:67-81.
68. Rincover A, Koegel RL. 1975. Setting generality and stimulus control in autistic children. J Appl Behav Anal 8:235-246.
69. Romanczyk RG, Goren ER. 1975. Severe self-injurious behavior: the problem of clinical control. J Consult Clin Psychol 43:730-739.
70. Ross DL, Klykylo WM, Hitzemann R. 1987. Reduction of elevated CSF b-endorphin by fenfluramine in infantile autism. Pediatr Neurol 3:83-86.
71. Rutter M. 1996. Autism research: prospects and priorities. J Autism Dev Disord 26:257-275.
72. Sandman CA. 1988. B-endorphin disregulation in autistic and self-injurious behavior: a neurodevelopmental hypothesis. Synapse 2:193-199.
73. Sandman CA. 1990/1991. The opiate hypothesis in autism and self-injury. J Child Adolesc Psychopharmacol 1:235-246.
74. Sandman CA, Barron JL. 1992. Paradoxical response to sedative/hypnotics in patients with self-injurious behavior and stereotypy. J Dev Phys Disabil 4:1-10.
75. Sandman CA, Hetrick WP. 1995. Opiate mechanisms in self-injury. Ment Retard Dev Disabil Res Rev 1:130-136.
76. Sandman CA, Datta P, Barron JL, et al. 1983. Naloxone attenuates self-abusive behavior in developmentally disabled clients. Appl Res Ment Retard 4:5-11.
77. Sandman CA, Barron JL, Colman H. 1990. An orally administered opiate blocker, naltrexone attenuates self-injurious behavior. Am J Mental Retard 95:93-102.
78. Sandman CA, Barron JL, Chicz-DeMet A, et al. 1991. Brief report: plasma b-endorphin & cortisol levels in autistic patients. J Autism Dev Disord 21:83-87.
79. Sandman CA, Hetrick WP, Taylor DV, et al. 1993. Naltrexone reduces self-injury and improves learning. Exp Clin Psychopharmacol 1:242-258.
80. Sandman CA, Hetrick WP, Taylor DV et al. 1997. Dissociation of POMC peptides after self-injury predicts responses to centrally acting opiate blockers. Am J Ment Retard 102:182-199.
81. Sandman CA, Thompson T, Barrett RP, et al. 1998. Opiate blockers. In: Aman M, Reiss S, editors. Consensus handbook on psychopharmacology. Columbus, OH: Ohio State University. p 291-302.
82. Sandman CA, Hetrick W, Taylor DV, et al. Long-term effects of naltrexone on self-injurious behavior. Am J Ment Retard in press.
83. Sato H, Mori S. 1997. Subregional assignment of the proopiomelanocortin gene (POMC) to human chromosome band 2p23.3 by fluorescence in situ hybridization. Cytogenet Cell Genet 76:221-222.
84. Schrain RJ, Freedman C. 1961. Studies of 5-hydroxyindol metabolism in autistic and other mentally retarded children. J Pediatr 58:315-320.
85. Schroeder SR, Rojahn J, Mulick JA. 1978. Ecobehavioral organization of developmental day care for the chronically self-injurious. J Pediatr Psychol 3:81-88.
86. Seidah NG, Chretien M. 1992. Proprotein and prohormone convertases of the subtilisin family. Trends Endocrinol Metab 3:133-140.
87. Seidah NG, Marcinkiewicz M, Benjannet S, et al. 1991. Cloning and primary sequence of a mouse candidate prohormone convertase PC1 homologous to PC2, furin, and KEX 2: distinct chromosomal localization and messenger RNA distribution in brain and pituitary compared to PC2. Mol Endocrinol 5:111-122.
88. Shen K, Crain SM. 1992. Chronic selective activation of excitatory opioid receptor functions in sensory neurons in opioid 'dependence' without tolerance. Brain Research 597:74-83.
89. Shutt DA, Smith AI, Wallace CA, et al. 1988. Effect of myiasis and acute restraint stress on plasma levels of immunoreactive b-endorphin, adrenocorticotrophin (ACTH) and cortisol in the sheep. Aust J Biol Sci 41:297-301.
90. Smart D, Lambert DG. 1996. The stimulatory effects of opioids and their possible role in the development of tolerance. Trends in Pharmacological Sciences 17:264-269.
91. Smith SG, Gupta KK, Smith SH. 1995. Effects of naltrexone on self injury, stereotypy, and social behavior of adults with developmental disabilities. Journal of Developmental and Physical Disabilities 35:283-323.
92. Spence MA, Simmons JQ, Brown NA, et al. 1973. Sex ratios in families of autistic children. Am J Ment Defic 77:405-407.
93. Strand FL. 1999. Neuropeptides: regulators of physiological processes. Cambridge, MA: MIT Press.
94. Thompson T, Hackenberg T, Cerutti D, et al. 1994. Opioid antagonist effects on self-injury in adults with mental retardation: Response form and location as determinants of mediation effects. Am J Ment Retard 99:85-102.
95. Walter AS, Barrett RP, Feinstein AM et al. 1990. A case report of naltrexone treatment of self-injury and social withdrawal in Autism. Journal of Autism and Developmental Disorders 20:169-176.
96. Wei E, Loh H. 1976. Physical dependence of opiate-like peptides. Science 193:1242-1243.
97. Weizman R, Weitman A, Tyano S, et al. 1984. Humoral-endorphin blood levels in autistic, schizophrenic and healthy subjects. Psychopharmacology 82:368-370.
98. Willemsen-Swinkels SHN, Buitelarr JK, Nijhof GJ, et al. 1995. Failure of naltrexone to reduce self-injurious and autistic behavior in mentally retarded adults. Arch Gen Psychiatry 52:766-773.
99. Wing L. 1989. The diagnosis of autism. In: Gillberg C, editor. Diagnosis and treatment of autism. New York: Plenum Press. p 5-22.
100. Zheng M, Streck RD, Scott REM, et al. 1994. The developmental expression in rat of proteases furin, PC1, PC2, and carboxypeptidase E: implications for early maturation of proteolytic processing capacity. J Neurosci 14:4656-4673.
101. Zukin RS, Sugarman JR, Fitz-Syage G et al. 1982. Naltrexone-induced opiate receptor supersensitivity. Brain 245:285-292.